Roland Rott Sells 3,577 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) Stock

GE HealthCare Technologies Inc. (NASDAQ:GEHC) CEO Roland Rott sold 3,577 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the transaction, the chief executive officer now owns 24,298 shares in the company, valued at approximately $2,101,291.04. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

GE HealthCare Technologies Price Performance

NASDAQ GEHC opened at $88.33 on Friday. The firm has a market capitalization of $40.36 billion, a PE ratio of 24.27, a P/E/G ratio of 3.12 and a beta of 1.24. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.98. GE HealthCare Technologies Inc. has a 12 month low of $66.39 and a 12 month high of $94.55. The company’s 50 day simple moving average is $88.88 and its 200 day simple moving average is $83.52.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.08. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The company had revenue of $4.86 billion for the quarter, compared to the consensus estimate of $4.87 billion. During the same quarter in the previous year, the business earned $0.99 EPS. The company’s quarterly revenue was up .9% compared to the same quarter last year. As a group, equities research analysts forecast that GE HealthCare Technologies Inc. will post 4.29 EPS for the current fiscal year.

GE HealthCare Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Friday, October 18th will be given a dividend of $0.03 per share. The ex-dividend date is Friday, October 18th. This represents a $0.12 annualized dividend and a dividend yield of 0.14%. GE HealthCare Technologies’s dividend payout ratio (DPR) is 3.30%.

Institutional Trading of GE HealthCare Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in GEHC. Vanguard Group Inc. grew its position in GE HealthCare Technologies by 9.2% in the first quarter. Vanguard Group Inc. now owns 48,519,340 shares of the company’s stock worth $4,410,893,000 after buying an additional 4,107,746 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of GE HealthCare Technologies by 27.5% during the 2nd quarter. Bank of Montreal Can now owns 696,446 shares of the company’s stock worth $54,964,000 after acquiring an additional 150,137 shares in the last quarter. Sei Investments Co. grew its holdings in shares of GE HealthCare Technologies by 30.6% in the 1st quarter. Sei Investments Co. now owns 279,336 shares of the company’s stock worth $25,393,000 after acquiring an additional 65,476 shares during the last quarter. Chevy Chase Trust Holdings LLC raised its position in shares of GE HealthCare Technologies by 7.1% during the first quarter. Chevy Chase Trust Holdings LLC now owns 235,436 shares of the company’s stock worth $21,403,000 after purchasing an additional 15,522 shares during the period. Finally, Douglas Lane & Associates LLC lifted its holdings in shares of GE HealthCare Technologies by 2.2% during the third quarter. Douglas Lane & Associates LLC now owns 460,004 shares of the company’s stock valued at $43,171,000 after purchasing an additional 10,099 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on GEHC shares. Redburn Atlantic raised shares of GE HealthCare Technologies to a “strong-buy” rating in a report on Thursday, August 1st. Evercore ISI boosted their price objective on GE HealthCare Technologies from $98.00 to $102.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. BTIG Research upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Wednesday, September 18th. Stifel Nicolaus raised their target price on GE HealthCare Technologies from $100.00 to $102.00 and gave the company a “buy” rating in a research note on Monday, September 30th. Finally, UBS Group lowered shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $84.00 to $74.00 in a research report on Thursday, September 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $94.36.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.